N V Khalo studies how well a medication called Revelise (alteplase) works in treating ischemic strokes, which occur when blood flow to the brain is blocked. His research involves a significant number of patients, many of whom are older and may have other health problems. Khalo examines not only how effective the treatment is in improving patient outcomes but also the safety of using this therapy in diverse populations.
Key findings
In a study of 2,202 patients, 49.9% had good outcomes when discharged after receiving Revelise.
After 90 days, the percentage of patients with good outcomes increased to 66.4%.
The study demonstrated that Revelise effectively reduces disabilities related to strokes, even among older patients and those with various health issues.
Frequently asked questions
Does Dr Khalo study stroke treatments?
Yes, Dr Khalo studies treatments for ischemic strokes, focusing on the medication Revelise.
What outcomes have been observed with Revelise?
His research indicates that nearly 50% of stroke patients show good recovery outcomes after treatment with Revelise, increasing to over 66% at 90 days.
Is Dr Khalo's work relevant to older stroke patients?
Absolutely, his findings specifically include older patients and those with other health problems, confirming the treatment's effectiveness for these groups.
Publications in plain English
[Fortelyzin for acute ischaemic stroke treatment in an extended (4.5 to 24 hours from the onset of symptoms) time window: data from the observational study FORPI registry].
2026
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Shamalov NA, Martynov MY, Gusev EI, Marskaya NA, Khasanova DR +27 more
Plain English This study looked at the use of the drug Fortelyzin to treat patients who had an acute ischemic stroke (AIS) when they received treatment between 4.5 and 24 hours after their symptoms started. Researchers found that 61% of patients treated within the first 4.5 hours had a good recovery, while 65% of those treated later also had a good recovery, showing that treatment is still effective even when started later. The rates of serious complications were similar in both groups, indicating that Fortelyzin is a safe option for stroke patients, regardless of when they receive treatment.
Who this helps: This helps stroke patients who may not get to the hospital within the first few hours of their symptoms.
[Fortelizin in bridging therapy of acute ischemic stroke: data from the observational study FORPI registry].
2026
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Shamalov NA, Martynov MY, Gusev EI, Khasanova DR, Nesterova VN +27 more
Plain English This study looked at how safe and effective a drug called Fortelyzin is for people having an acute ischemic stroke, specifically when used during treatments that involve both thrombolysis and thrombectomy. Out of 1,116 patients, 38% had a good recovery after 90 days, while 29% died in that time. The findings are important because they show that Fortelyzin can be a useful option in treating stroke patients in everyday healthcare settings.
Who this helps: This benefits doctors and patients dealing with acute ischemic strokes.
Plain English This study looked at how new treatments for ischemic stroke (IS) are being used in Russia from 2015 to early 2025. Researchers found that more patients are getting treated quickly after symptoms start, with those admitted within 4.5 hours rising from 23% in 2015 to 31% in 2024. The use of reperfusion treatments, like IVT and thrombectomy, also increased significantly, leading to a reduction in mortality rates from 16.8% in 2015 to 12.6% in 2025. This matters because faster and better treatment can help more people survive strokes and recover their abilities.
Who this helps: This helps patients who suffer from strokes and improve outcomes through timely medical interventions.
Plain English This study looked at how using teleconsulting in primary vascular units (tele-PVUs) improved access to specialized stroke treatment in Russia. It found that 9.8% of stroke patients treated in these units received thrombolytic therapy, which is higher than the national average, and the time from when symptoms started to when treatment began was also reduced. This is important because it means more patients in rural areas can get life-saving treatment faster.
Who this helps: Patients in rural areas who suffer from ischemic strokes.
[Fortelyzin for acute ischaemic stroke treatment: an open, prospective, non-interventional, observational study FORPI registry].
2025
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Shamalov NA, Martynov MY, Gusev EI, Marskaya NA, Khasanova DR +92 more
Plain English This study looked at how safe and effective the drug Fortelyzin is for treating patients with acute ischemic stroke (AIS). Researchers followed 17,636 patients across 329 centers between March 2021 and October 2024. They found that 61% of patients experienced good outcomes after 90 days, and only 2% had serious bleeding complications, which is similar to results from previous studies. This is important because it supports the use of Fortelyzin for patients suffering from strokes, potentially leading to better treatment options.
Who this helps: Patients with acute ischemic stroke and their healthcare providers.
[Thrombolytic Therapy for Ischemic Stroke with Revelise: Results of a Two-Year Follow-Up in the International PRIMA Study].
2025
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Shamalov NA, Khasanova DR, Marchenko SV, Soldatov MA, Azarova AG +46 more
Plain English This study looked at how well and safely Revelise (alteplase), a medication for treating ischemic stroke (IS), works in real-life situations. It involved 2,202 patients, mostly around 68 years old, and found that nearly half (49.9%) of them had good outcomes when discharged, rising to 66.4% after 90 days. The results showed that Revelise effectively reduces stroke-related disabilities, even in older patients and those with other health issues.
Who this helps: This benefits patients who suffer from ischemic strokes and the doctors treating them.
[Neutrophil respiratory burst and the state of hemostasis in patients with ischemic and hemorrhagic stroke].
2018
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Savchenko AA, Pavlova OM, Khalo NV, Gvozdev II
Plain English This study looked at how certain immune cells called neutrophils behave and how that relates to blood clotting in patients who have experienced either ischemic stroke (IS) or hemorrhagic stroke (HS). Researchers found that patients with hemorrhagic stroke had a stronger immune response, with higher levels of reactive oxygen species (ROS) produced by neutrophils and different blood clotting patterns than those with ischemic stroke. This matters because understanding these differences can help doctors better manage stroke treatment and improve patient outcomes.
Who this helps: Patients with strokes, particularly those with hemorrhagic strokes.